Your browser doesn't support javascript.
loading
Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry.
Viskochil, David; Clarke, Lorne A; Bay, Luisa; Keenan, Hillary; Muenzer, Joseph; Guffon, Nathalie.
Affiliation
  • Viskochil D; Department of Pediatrics, Division of Medical Genetics, University of Utah School of Medicine, Salt Lake City, Utah.
  • Clarke LA; British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Bay L; Hospital Nacional de Pediatría J. P. Garrahan, Ciudad Autónoma de Buenos Aires, Argentina.
  • Keenan H; Sanofi Genzyme, Cambridge, Massachusetts.
  • Muenzer J; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Guffon N; Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Femme Mère Enfant, Lyon, France.
Am J Med Genet A ; 179(12): 2425-2432, 2019 12.
Article in En | MEDLINE | ID: mdl-31639289
ABSTRACT
Mucopolysaccharidosis Type I (MPS I), caused by deficiency of α-L-iduronidase results in progressive, multisystemic disease with a broad phenotypic spectrum including patients with severe (Hurler syndrome) to attenuated (Hurler-Scheie and Scheie syndromes) disease. Disordered growth is common with either phenotype. The study objectives were to construct sex- and age-specific estimated length/height and head circumference growth curves for untreated individuals with severe and attenuated disease and compare them with clinical reference standards. Untreated individuals in the MPS I Registry with at least one observation for length/height and/or head circumference and assigned phenotype as of May 2017 were included. Median growth for 463 untreated individuals with severe disease deviated from reference growth curves by ~6 months of age and fell below the third percentile by 4 years of age. Median head circumference was above reference curves from 3 to 4 months through 3 years of age. Among 207 individuals with untreated attenuated disease, median height fell below the third percentile by 9 years of age with divergence from reference curves by 2 years of age. MPS I-specific growth curves will be useful in evaluation of long-term outcomes of therapeutics interventions and will provide a foundation for understanding the pathogenesis of skeletal disease in MPS I.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Phenotype / Mucopolysaccharidosis I / Growth Charts Type of study: Guideline / Screening_studies Limits: Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Phenotype / Mucopolysaccharidosis I / Growth Charts Type of study: Guideline / Screening_studies Limits: Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Year: 2019 Type: Article